

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: C07K 14/18, A61K 39/29, G01N 33/68		A1	(11) International Publication Number: WO 95/27733 (43) International Publication Date: 19 October 1995 (19.10.95)
<p>(21) International Application Number: PCT/US95/03935</p> <p>(22) International Filing Date: 7 April 1995 (07.04.95)</p> <p>(30) Priority Data: 08/224,973 8 April 1994 (08.04.94) US</p> <p>(71) Applicant (for all designated States except US): THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES [US/US]; National Institutes of Health, Office of Technology Transfer, Suite 325, 6011 Executive Boulevard, Rockville, MD 20852 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): BERZOFSKY, Jay, A. [US/US]; 9321 Corsica Drive, Bethesda, MD 20814 (US). FEINSTONE, Stephen [US/US]; 3021 Cathedral Avenue, N.W., Washington, DC 20008 (US). SHIRAI, Mutsunori [JP/JP]; 1239-2 Ikenobe, Miki-chou, Kita-gun, Kagawa 761-01 (JP).</p> <p>(74) Agents: SVENSSON, Leonard, R. et al.; Birch, Stewart, Kolasch & Birch, P.O. Box 747, Falls Church, VA 22046-0747 (US).</p>			
<p>(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIP0 patent (KE, MW, SD, SZ, UG).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>			
<p>(54) Title: HEPATITIS C VIRUS CORE PEPTIDE FOR STIMULATION OF CYTOTOXIC T LYMPHOCYTES AND DIAGNOSIS OF HCV EXPOSURE</p> <p>(57) Abstract</p> <p>Peptides representing portions of the Hepatitis C Virus core protein that represent cytotoxic T lymphocyte epitopes are disclosed. The peptides also have amino acid sequences corresponding to binding motifs for human HLA molecules. The peptides are useful as vaccines for the prevention or treatment of Hepatitis C Virus infection and can also be used as reagents for diagnostic tests for Hepatitis C Virus exposure or for prognostic tests for predicting the clinical course of Hepatitis C Virus infection.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Bahamas	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

HEPATITIS C VIRUS CORE PEPTIDE FOR STIMULATION OF
CYTOTOXIC T LYMPHOCYTES AND DIAGNOSIS OF HCV EXPOSURE

BACKGROUND OF THE INVENTION

Field of the Invention

The present invention is directed to peptides derived from the core protein of the Hepatitis C Virus (HCV). The peptides are those which elicit a cytotoxic T lymphocyte (CTL) response in an immunized host. The invention is also directed to vaccines for prevention and treatment of HCV infection and diagnostic methods for detection of HCV exposure in patients.

10 Description of Related Art

Hepatitis C virus is not only the cause of most cases of parenterally acquired non-A, non-B hepatitis, but also is responsible for a large portion of sporadic community acquired acute viral hepatitis, chronic 15 hepatitis of unknown origin, cryptogenic cirrhosis and probably hepatocellular carcinoma (2,18,37,54). It is the propensity of this virus to cause chronic infections and chronic liver disease that makes it such a medically important problem. Therefore, there is an important 20 need for a vaccine to protect against infection by this virus and diagnostic tests to assess exposure of patients to HCV.

HCV is a single-stranded plus sense RNA virus (10) and has been classified as a member of the Flaviviridae 25 family (8,28). The structural proteins of the virus consist of the core, which forms the nucleocapsid, and two envelope glycoproteins E1 and E2.. Because the

envelope proteins are highly variable in sequence (33) and CTL clones may distinguish different isolates of HCV, as has been shown in HIV-1 studies (46,63,64), immunization with the envelope protein may not be an ideal approach for HCV. In contrast to the substantial amino acid sequence variation in the predicted envelope glycoproteins, the core protein of HCV shows greater sequence conservation among isolate groups (33) and is of particular interest for a vaccine to induce CTL. The conservation of core protein sequence also makes this protein a good target for a diagnostic method for assay of exposure to HCV based upon recognition of peptides of the HCV core protein by CTL in the exposed subject.

Like the related pestiviruses of animals, HCV infections may cause acute, self limited disease as well as chronic infections that result in chronic liver disease, cirrhosis and hepatocellular carcinoma. Neither the mechanism of chronicity nor the pathogenesis of the liver disease is understood. An immune escape mechanism has been proposed to account for the chronic infections based on a hypervariable region that has been identified within the E2 protein (29,70). Multiple sequences in this hypervariable region can be obtained from the same patient at the same time though one sequence usually predominates. Weiner et al. have suggested that the predominant sequence changes over time under immune selection, and that this hypervariable region is the major neutralization epitope of the virus (71). Experimental inoculations and challenge experiments in chimpanzees have also failed to demonstrate that these animals mount an effective protective antibody response following infection (23,53).

Therefore, it is important to define the T cell responses in HCV infections and to determine how they relate to immunity as well as pathogenesis. As T cell epitopes may be found in non-structural components of the virus and therefore may not be under the same

immunologic pressure as the surface antigens, they may be important additions to a vaccine.

Cytotoxic T lymphocytes have been found to mediate protection *in vivo* against certain virus infections 5 (19,51,52). The chronicity of infections as well as histopathologic findings indicate that HCV is probably not directly cytopathic (or cytolytic) in hepatocytes. Previous studies have reported that CD8⁺ CTL recognize epitopes within HCV proteins (38,60). The addition of 10 CTL epitopes to a potential vaccine might overcome some of the problems apparent with vaccines produced from only the surface glycoproteins.

Class I and class II MHC molecules allow T cells to recognize polypeptide fragments of protein following 15 processing of foreign antigens (3,26,56,59,66,73). In particular, class I MHC molecules sample and present peptides cleaved from endogenously synthesized proteins, including those of infecting viruses, allowing CD8⁺ CTL to carry out immune surveillance against virally 20 infected cells. Therefore, any viral protein synthesized in the cell, even if it is not expressed intact on the cell surface, is a potential target for such CTL. Synthetic peptide vaccines are advantageous in that they may elicit fewer deleterious immune 25 responses than a whole protein or attenuated or killed virus immunogen (4).

SUMMARY OF THE INVENTION

The invention resides in part in peptides representing CTL epitopes of the core protein of HCV. 30 The peptides are representative of those fragments of HCV presented on the surface of HCV infected cells bound to MHC molecules.

The peptides can be used both as an immunogen, as part of a vaccination protocol, or as a diagnostic or 35 prognostic tool. In the former application, the peptides are formulated into vaccines and administered

to a subject for the prevention or treatment of HCV infection. In the diagnostic and prognostic applications, the peptides can be contacted with immune cells from a patient. The response of the immune cells 5 to the peptide is then assessed.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a series of 11 peptides selected by the amphipathicity algorithm for prediction of T cell epitopes from the amino acid sequence of the HCV core 10 protein. The sequences of the synthesized peptides were based on the HCV-H isolate. Residues which differ from the published sequences (29,32,48,70) are shown with underlines.

Figures 2A-2C show the results of tests of CTL 15 specific for C7 for their phenotype, MHC-restriction, and fine specificity using overlapping peptides. Cells of a short-term CTL line derived from vHCV#4-immune spleen cells, restimulated with C7 at 10 μ M, together with irradiated syngeneic spleen cells, and a 1:10 20 dilution of the supernatant of a culture of spleen cells stimulated with concanavalin A (a source of cytokines), were used as effectors. Lysis in the absence of peptide was less than 7% in the experiments shown in Figs. 2A-2C. Target cells were sensitized in the presence of 25 peptide (10 μ M). Effector/ Target ratio = 100/1. Data are the means of triplicate samples with an SE of less than 5% and are representative of at least two independent experiments.

Fig. 2A; the phenotype of the H-2^d CTL specific for C7. 30 The CTL assay was performed in the presence of anti-L3T4 (GK 1.5) (anti-CD4) or anti-Lyt 2.2 (2.43) (anti-CD8) monoclonal antibodies (culture supernatant) at the dilution of 1:4, or no antibody, for 6 h. 18Neo was sensitized in the presence of C7 (10 μ M).

Fig. 2B; the MHC class I molecules responsible for the 35 presentation of C7 to CTL in the H-2^d strain. Each

transfectant expresses only one class I molecule from H-2d (T4.8.3, D^d; T1.1.1, L^d; and B4III2, K^d) or none (L28). The parent cell in each case is a DAP3 L cell (H-2^k).

Fig. 2C; fine specificity of murine H-2D^d-restricted CTL specific for C7. CTL activity was tested on H-2^d 3T3 fibroblast target cell line 18Neo in the presence of titrated concentrations of the following overlapping decapeptides, SEQ ID NOS:1-8, respectively, contained in C7, as well as the HLA-A2 motif nonapeptide C7A2 (see Fig. 1) and the full-length C7 peptide:

C7 (129-144)	G F A D L M G Y I P L V G A P L
C7-L10G	G Y I P L V G A P L
C7-P10M	M G Y I P L V G A P
C7-A10	L M G Y I P L V G A
15 C7-G10	D L M G Y I P L V G
C7-V10	A D L M G Y I P L V
C7-L10F	F A D L M G Y I P L
C7-P10G	, G F A D L M G Y I P

Figure 3 shows the HLA restriction of human CTL specific for C7 in a patient with HCV infection. Human CTL activity specific for C7 from a patient with chronic hepatitis C (No.7 in Table 4) tested for the cytotoxicity against the autologous target cell in the presence of C7 10 μ M with anti-HLA class I (W6/32, IgG2a) or anti-HLA class II DR (L-243, IgG2a) at 1:4 dilution or no antibody. The PBL were stimulated twice with mitomycin C-treated PBL and peptide C7 as described in "Material and Methods". The lysis in the absence of peptide is less than 5%. Data are the means of triplicate samples with an SE of less than 5% and are representative of at least two independent experiments.

Figure 4 presents data showing that Human CTL recognize a nonamer segment of C7 presented by HLA-A2. PBL from patient #7 with chronic hepatitis C and #8 with acute hepatitis C (Table 4) were stimulated twice

in vitro with mitomycin C-treated autologous PBL and peptide C7 as described in Materials and Methods, and tested at an effector-to-target ratio of 100: 1 in the presence of peptide C7, the nonamer peptide C7A2 (DLMGYIPLV), or no peptide against the following targets: autologous EBV-transformed B lymphoblastoid cells (HLA-A1,A2, B51, Bw4, Bw6 for #7) or autologous Con A blast targets for #8 (A2, B51 for #8) (autologous cells indicated by *), allogeneic EBV-transformed B lymphoblastoid cells (HLA-A24,31,B51,54,w4,w6,Cw1; or HLA-A26,w33, B12,15, Cw3), the C1R cell line (39) (HLA-A-neg, B-neg., Cw4, DR8, DPw4, DQ3) either transfected with HLA-A2.1 (C1R-A2) (39) or untransfected (C1R). Data are the means of triplicate cultures with all SEM < 5%, and are representative of at least two independent experiments.

Figure 5 shows an alignment of HCV core protein sequences resident in GENBANK on April 5, 1994 and the HCV-H sequence (FDA) used in the working examples. Amino acid residues in bold indicate residues that vary among sequences.

DETAILED DESCRIPTION OF THE INVENTION

The peptides of the present invention have an amino acid sequence derived from the sequence of the core protein of the HCV virion. Several isolates of HCV have been obtained and the amino acid sequence of the core protein was found to be >95% identical among all of them (33). The amino acid sequences of core protein from several HCV isolates is presented in Figure 5. The HCV-H isolate, used for the present working examples, is shown on the top line (FDA). The alignment shows that the carboxyl terminus of the core protein diverges significantly among the isolates sequenced.

As described in more detail in the Examples, the

conservation of the core protein sequence is advantageous with respect to design of a peptide vaccine and diagnostic reagent. The CTL elicited in response to immunization with peptides of the present invention attack infected cells rather than free virions. Because fragments of all of the proteins endogenously synthesized by a cell are displayed on the surface of the cell, bound to MHC molecules, the fact that the core protein is not localized to the surface of the virion particle is not problematic.

Furthermore, the mechanism of processing of endogenous proteins for display by the MHC is such that it is expected that any collinear peptide that can be obtained by random proteolysis of a protein is likely to be generated at early steps in the processing. The particular MHC complexes expressed by an individual appear to be responsible for selection of the particular peptides that are actually found on the surface of cells of the individual (26). Thus, a person having an HLA-A11 haplotype will likely display different peptides from a particular protein than are displayed by a person having an HLA-A2 haplotype.

The particular rules explaining selection of peptides that bind to particular MHC haplotypes are not fully defined. However, what is known of the structure-binding relationship has been summarized in "motifs" for peptide binding to MHC haplotypes. A table of motifs published in the literature to date has been compiled by Gabriel Meister and Dr. Anne DeGroot at Brown University (Providence, RI) and is presented as Table 1.

Table 1: NATURAL PEPTIDE MOTIFS

Position in peptide

Motif haplotype	Residue "rank"	1	i+1	i+2	i+3	i+4	i+5	i+6	i+7	i+8	i+9	i+10
HLA-A2.1 (a)	anchor	L										
	strong	M		E, K			V		K			
HLA-A2.1 (b)	anchor			A, V, I, L,	A, V, I,	A, V, I,						
	strong			Y, F, W, M,	L, Y, F,	L, Y, F,						
HLA-A3	anchor	L		C	W, M, C	W, M, C						
	strong								V, K			
HLA-A11 (a)	anchor	L, I, V										
	strong		*									
HLA-A11 (b)	anchor		L, I				L, S, T,					
	strong						G, A					
	weak							L, S, T,				
							G, A					
							V					

Table 1: NATURAL PEPTIDE MOTIFS

HLA-A11 (c)	anchor	strong	weak	*	I	R, I	S, T, G, A	K	
HLA-AGB (a)	anchor	strong		V, S, T	V			R, K, H	
HLA-AGB (b)	anchor	strong		V, S, T	A, V, I, L, Y, F, W, M, C			R, K, H	
HLA-B8 (a)	anchor	strong		V, S, T	A, V, I, L, Y, F, W, M, C			R, K, H	
HLA-B8 (b)	anchor	strong		R				L	
HLA-B8 (c)	anchor	strong		R, K	R	R, K	W, Y	I, L	

Table 1: NATURAL PEPTIDE MOTIFS

Table 1: NATURAL PEPTIDE MOTIFS

HLA-B53 (b)	anchor	P		I			
	strong						
	weak	S, Y, F, M	F, K, N, Q	I, L, Q	L	Y	
HLA-DR1 (a) ‡	anchor	Y, F, W		M, L			
HLA-DR1 (b)	anchor	Y, F		M, L			
	strong						
HLA-DR1 (c)	anchor	A, V, I, L, Y, F, W, M, C			S, T, A, V, I, L, P, C		A, V, I, , L, Y, F, W, M , C
HLA- DR (2, 5, 7)	anchor	Y, F, W, I, L, V			S, T, A, V, G, I, L, P, C		
HLA- DR2 a/DR2 b	anchor	I, L, V					R, K, H
HLA- DR3 /DRw52 (a)	anchor	F, I, L, V, Y		D, N, S, T			

Table 1: NATURAL PEPTIDE MOTIFS

HLA-DR3 (b)	anchor	A, V, I, L, Y, F, W, N, C	A, V, I, L, Y, F, W, M, C	Q, N, R, K, D, E, S, T	R, K, H		
HLA-DR4 (a)	anchor	F, L, V				N, Q, S, , T	
HLA-DR4 (b)	anchor	W, Y		M, A	T	L, Q	
	strong			V, L	S	M, N	
HLA-DR7	anchor	F, I, L, V, Y			N, S, T		
HLA-DR8	anchor	F, I, L, V, Y			H, K, R		
HLA-DRw11 (5)	anchor	W		M, L	R		
	strong			V	K		
HLA-DRw17	anchor			I, L, V	D, E		
H-2-Db	anchor			N		M, I	
	strong			I, L, T, V	L, F		
H-2-Dd (a)	anchor	G	P		R, K, H		L, I, F

Table 1: NATURAL PEPTIDE MOTIFS

H-2-Dd(b)	anchor	G	P	R, K, H	L, I, F
H-2-Kb	anchor	Y		F, Y	I, M
H-2-Kd	anchor				I, L, V
H-2-RK	anchor	B			I
H-2-Ld	anchor	P		K, R	M, L, F
I-Ed (a)	anchor	R, K, H	R, K, H	A, C, F, G, I, L, M, P, S, T, V, Y	R, K, H
I-Ed (b)	anchor	K, R, H	K, R, H	A, C, F, G, I, L, M, P, S, T, V, Y	K, R, H
I-Ed (c)	anchor	K, R, H	K, R, H	A, C, F, G, I, L, M, P, S, T, V, Y	K, R, H
I-Ek (a)	anchor	A, V, I, L, S, T, Y, F, W	A, V, I, L, S, T, Y, F, W		K, R, H

Table 1: NATURAL PEPTIDE MOTIFS

I-ERK(b)	anchor	A, V, I, L, S, T, Y, F, W	A, V, I, L, S, T, Y, F, W	K, R, H

*1 - small side-chain residue, including L, S, D, T, G, A. Similarly, no K, R, or H.

*2 - hydrophobic residue, including I, Y, F, W, L, V, S, A.

*3 - Relatively hydrophobic residue, including L, M, A, I, G, S, T, V, Q

‡ - Original publication calls for exclusion of D, E from the peptide

As described below, the C7 peptide was found first by actual testing for CTL activity and was later found to have a sequence consistent with the HLA-A2 binding motif. The C7 peptide is expected to be useful in only 5 the population which has the HLA-A2 haplotype. However, since this is 40-50% of the human population, this is a significant population.

Furthermore, peptides containing binding motifs for additional HLA types are identifiable within the 10 peptides used in Examples 1 and 2. For example the C1, C2, C4, C6 and C8 peptides (see Figure 1) have binding motifs for human HLA-A68, HLA-A68, HLA-A68, HLA-B8, and HLA-B27, respectively. To determine the usefulness of 15 these peptides, each is tested for CTL activity, a positive result confirming that the particular peptide is effective for eliciting a CTL response and can be used as a diagnostic reagent for subjects having the corresponding MHC (HLA in human subjects) haplotype.

General Experimental Materials and Methods

20 **Mice.** BALB/c mice and C57BL6 mice were purchased from Japan Charles River Laboratories (Tokyo, Japan). Mice used were 8 weeks old.

25 **Recombinant Vaccinia Viruses.** Recombinant vaccinia virus expressing the HCV structural genes C, E1, and E2, as well as NS2 (FDA isolate of the H strain HCV(H) (24)) (vHCV#4) was made by the method of Chakrabarti et al. (9) and used for immunizing the mice to generate HCV core specific CTL. vSC8 (recombinant vaccinia virus containing the *Escherichia coli* lacZ gene), a generous 30 gift of Dr. Bernard Moss, NIAID, NIH, has been described (9) and was used as a control vaccinia for immunizing the mice.

35 **Peptide Synthesis and Purification.** HCV core peptides according to the predicted amino acid sequence of HCV(H) (24) (unpublished) were prepared by the simultaneous multiple peptide method of solid-phase

peptide synthesis, in polypropylene mesh "tea-bags" as described (31). Peptides were desalted by reverse-phase chromatography on C18 Sep-Pak columns (Waters Associates, Milford, MA), purified and analyzed by HPLC.

5 **CTL Generation.** Mice were immunized intravenously with 10^7 PFU of recombinant vaccinia virus. 4-6 weeks later, immune spleen cells (5×10^6 /ml) in 24-well culture plates in complete T cell medium (CTM; 1:1 mixture of RPMI 1640 and EHAA medium containing 10% FCS, 2mM L-glutamine, 100 U/ml penicillin, 100 μ g/ml streptomycin and 5×10^{-5} M 2-ME) were stimulated for 6 days in vitro with peptides or vHCV#4-infected (1 hour, 37°C, multiplicity of infection of 10:1) irradiated syngeneic spleen cells (2.5×10^6 /ml well, three washings before culture) and 10% Con A supernatant-containing medium (Rat T Stim, Collaborative Research, Inc., Bedford, MA), and restimulated with irradiated syngeneic spleen cells (2.5×10^6 /ml well) and peptides at day 7, and addition of 10% rat T stim and replacement of 0.5 ml culture medium by fresh CTM at day 8 and 11. At day 7 or 14 of the culture, the stimulated cells were used as effectors in a CTL assay.

20 **CTL Assay.** Cytolytic activity of in vitro secondary CTL was measured as previously described (62, 67) using a 6-hour assay with ^{51}Cr -labeled targets. For testing peptide specificity of CTL, effectors and ^{51}Cr -labeled targets were mixed with various concentrations of peptide. The percent specific ^{51}Cr release was calculated as $100 \times [(\text{experimental release} - \text{spontaneous release}) / (\text{maximum release} - \text{spontaneous release})]$. Maximum release was determined from supernatants of cells that were lysed by addition of 5% Triton-X 100. Spontaneous release was determined from targets cells incubated without added effector cells. The 18Neo (H-2^d; class I MHC⁺, class II MHC neomycin-resistance gene-transfected 3T3 fibroblast (62)) and EL4 thymoma cells (H-2^b) were used as targets.

5 **Blocking of CTL response by antibodies.** Culture supernatant of hybridomas GK1.5 or 2.43 containing anti-L3T4 (anti-CD4, IgG2b (72) or anti-Lyt 2.2 (anti-CD8 (58)) antibodies, respectively, were added to the 96 well plates of CTL assay, at the indicated concentrations.

10 **Class I MHC transfecants.** Mouse L cell transfecants with D^d, L^d (21,41,43,45) were the kind gifts of Dr. David Margulies, NIAID. The transfecant expressing K^d was developed by Abastado et al. (1) and was a kind gift of Dr. Keiko Ozato (NICHD). All 15 transfecant cell lines were examined by FACS analysis with an appropriate panel of anti-H-2D^d, anti-H-2K^d, and anti-H-2L^d mAbs to confirm their expressed phenotype before the performance of the functional studies reported here. The human C1R cell line (39) (HLA-A-neg, B-neg., Cw4, DR8, DPw4, DQ3) either untransfected (C1R) or transfected with HLA-A2.1 (C1R-A2) (39) was a kind gift of Dr. Victor Engelhard, University of Virginia.

20 **Example 1: Identification Of A CTL Epitope In The Core Protein Of HCV**

25 Based on the predicted amino acid sequence of the core protein of the HCV-H isolate, a series of 11 overlapping peptides covering 72.3% of the HCV core sequence and selected on the basis of amphiphaticity (13,17,40) as potential T-cell epitopes, were synthesized. The FORTRAN source code of the computer program used for the selection has been published as an appendix to reference 75. Comparison of the predicted 30 amino acid sequence of the core region of HCV-H to other published isolates (32,36,65) showed that three of the peptides had substitutions in one or two residues compared to the published sequence (Fig.1). To generate CTL specific for the peptides in mice, the spleen cells of mice immunized with the recombinant vaccinia virus 35 were stimulated *in vitro* with peptides. BALB/c mice that were immunized with vHCV#4 developed CTL responses

to peptide C7 but not to any of the other peptides (Table 2). H-2^b mice showed no response to any peptide tested.

Table 2. CTL response to peptides from HCV core in H-2^d (BALB/c) mice and H-2^b (C57BL/6) mice.

Peptide	% specific ⁵¹ Cr release	
	H-2 ^d	H-2 ^b
1	4.7	-0.2
2	3.2	-1.1
3	3.2	0.0
4	3.2	-1.3
5	3.6	2.0
6	3.9	0.3
7	26.3	0.0
8	4.1	0.6
9	2.8	2.0
10	4.9	1.4
11	2.5	1.3

Mice were primed i.v. with 10⁷ plaque-forming units of recombinant vaccinia virus expressing the HCV-H core region (vHCV#4). The immune spleen cells were restimulated in vitro with peptides at 10 µM or no peptide in the presence of Con A supernatant (IL-2) for 13 days as described in "Material and Methods". CTL activity was measured against neo gene transfected 3T3 fibroblast cells (18Neo, H-2^d class I positive, class II negative) for BALB/c CTL and EL4 (H-2^b) for C57BL/6 CTL. Targets were sensitized with 10 µM of each peptide or no peptide for 6h. Effector / target (E:T) ratio 100:1, 5000 target cells/well. The lysis in the absence of peptide was <5% in BALB/c and C57BL/6. Data are the means of triplicate samples with an SE of < 5% and are representative of at least two independent experiments.

Specificity of CTL for the core protein was demonstrated at the level of lymphocyte priming *in vivo*, restimulation *in vitro*, and expression on the target cells in the CTL assay (Table 3). Only the recombinant 5 vaccinia virus expressing the core gene (vHCV#4), but not the control vaccinia viruses (vSC8), could prime mice for development of CTL specific for C7 (Table 3). The titration of the peptide concentrations used for 10 stimulation of immunized spleen cells demonstrated that C7 was required at a concentration of 1 to 10 μ M peptide for the stimulation of immune spleen cells to elicit the significant killing against H-2-matched target cells.

Because the CTL were generated by *in vitro* stimulation with peptide, it was important to confirm 15 that they recognized the processed products of endogenously synthesized core protein, not just peptide. The CTL restricted by H-2^d (BALB/c) were able to kill the vHCV#4-infected syngeneic target cells (18Neo cells, BALB/c 3T3 fibroblasts transfected with the neomycin 20 resistance gene) endogenously expressing core, as well as 18Neo cells in the presence of C7, but not the control targets, 18Neo infected with vSC8 (control vaccinia virus) or 18Neo in the absence of C7 (Table 3). Therefore, these 25 CTL were specific for processed products of endogenously synthesized HCV core protein, not only for exogenous peptide.

Treatment of the CTL specific for C7 with anti-CD8 monoclonal antibody reduced or abrogated cytotoxic

TABLE 3. Priming and boosting requirements for induction of CTL specific for C7
in H-2^d mice

Immunization	Restimulation	% Specific lysis			
		vHCV#4	vSC8	C7	C8
none	C7	2.8	1.6	0.5	1.4
vSC8	C7	1.3	2.6	3.6	4.2
	vHCV#4	70.6	64.4	3.9	4.7
	vSC8	68.8	64.3	3.2	4.8
vHCV#4	C7	17.7	4.8	24.8	2.3
	*C7	26.0	6.2	60.2	6.4
	C7 1 μ M	12.6	3.9	14.3	2.1
	C7 0.1 μ M	2.0	1.2	1.3	0.2
	vSC8	65.8	72.7	2.3	-0.1
	C8	2.2	1.7	1.0	1.7
					0.6

The ability of recombinant vaccinia viruses to prime and stimulate CTL specific for the products of inserted viral genes was used to generate CTL specific for HCV core in BALB/c (H-2^d) mice. Non-immune or immune spleen cells were restimulated in vitro with C7 10 μ M (or at the indicated concentrations) or vaccinia (vSC8) infected irradiated syngeneic spleen cells, and tested against vaccinia virus-infected I8Neo (1 h, 37°C, multiplicity of infection of 10:1, three washings before use) and I8Neo in the presence of the peptides (C7 10 μ M; C8 10 μ M) or no peptide at an E/T ratio of 100:1. vHCV#4, recombinant vaccinia virus expressing core & envelope of HCV-H; vSC8, control vaccinia virus; I8Neo, BALB/c 3T3 fibroblast, H-2^d. Data are the means of triplicate samples with an SE of < 5% and are representative of at least two independent experiments.

*vHCV#4 immune spleen cells, restimulated twice with C7 10 μ M and 10% ConA supernatant as described in "Material and Methods" and ref. (61).

activity on target cells, whereas anti-CD4 antibody did not (Fig. 2A). These data indicate that the effector cells which recognize C7 are conventional CD8⁺CD4⁻ (Lyt2⁺L3T4⁻) CTL. For H-2^d-restricted peptide specific 5 CTL in BALB/c, 18Neo cells expressing class I but not class II MHC gene products were used as targets. These facts, plus the MHC restriction to H-2^d, not H-2^b, indicated that these CTL are class I MHC restricted, as expected for Lyt2⁺ CD8⁺ effector T cells.

10 We used transfecants expressing D^d, L^d, or K^d molecules to determine which molecule was specifically required for the presentation of C7 in H-2^d. The targets were labeled with ⁵¹Cr and cocultured with the effector cells in the presence of peptide. T4.8.3 (D^d) was found 15 to present C7 (Fig. 2b), whereas neither L^d nor K^d presented C7 to the CTL. Therefore, D^d was necessary and sufficient to present this peptide.

20 In a titration study, C7 sensitized target cells for the lysis by the CTL at concentrations between 0.03-30 μ M (Fig. 2C). The lysis was approaching a plateau in the presence of C7 at concentrations above 1 μ M. Recognition of the same 16-residue peptide by CD8⁺ T cell with class I MHC molecules restriction could 25 represent presentation of a portion of the peptide by MHC molecules (20,25,55). To begin to map the peptide more finely, based on the observation that class I MHC molecules, including D^d in this case, tend to present peptides of 8-10 residues in length (15,22,26), we synthesized all seven overlapping decapeptides within 30 C7, overlapping by 9 residues each (see sequences in legend to Fig. 2C) as well as a nonapeptide C7A2 corresponding to the HLA-A2 motif (See Fig. 1 and results below). Of these, only C7-A10 (LMGYIPLVGA) was more active than the full-length C7 peptide (Fig. 2C). 35 Because neither of the overlapping decapeptides C7-G10 and C7-P10M is as active, we conclude that neither nonapeptide contained in these overlaps is sufficient

for optimal response. Therefore, the decapeptide C7-A10 appears to be the optimal peptide for recognition by these D^d-restricted CTL. Interestingly, this peptide does not contain the D^d motif as defined by endogenous peptides eluted from D^d (15) (see below).

We have induced murine CTL with ability to kill syngeneic target cells expressing the HCV core protein as well as targets incubated in the presence of peptide C7 (HCV residues 129-144 within core), in H-2^d mice, but 10 not in H-2^b mice. We conclude that H-2^d is an immune response (Ir) gene responder haplotype to C7 whereas H-2^b is not a responder. To determine which of the three H-2^d 15 class I molecules presents C7, we used L cell (H-2^d) transfectants expressing K^d, L^d, or D^d, and found that the C7 peptide required the D^d molecule for effective peptide presentation. Interestingly, the same MHC molecule was 20 found to present C7 (or more specifically C7-A10) here and the peptides P17 from HCV NS5 (60), as well as P18 (63) and HPS3 from HIV-1 gp160 (61), which share no striking similarity in sequences except similarity in amphipathicity profiles when folded as an alpha helix. Of these four peptides, only P18 has a clear D^d binding 25 motif as defined by endogenous peptides eluted from D^d, XGPX[K/R/H]XXX(X)[L/I/F], SEQ ID NO:9, (15). Thus, other motifs for binding D^d must exist as well. The identification of such novel D^d-binding peptides will aid 30 in the characterization of such new motifs. Although insufficient homology is present to define an obvious motif for D^d binding, analysis of residues involved in D^d binding (63) for each peptide may shed new light on the structural requirements for the D^d specificity.

To get the maximal killing, the peptide concentration required to stimulate CTL in vitro secondarily or to sensitize targets appeared to be 1 - 35 30 μ M for both C7 and C7-A10. This result suggests that these peptides bind with only moderate affinity to H-2D^d, compared with P18, an immunodominant CTL determinant of

HIV-1 gp160 restricted by D^d (62) with the D^d motif. Modifications of C7 or C7-A10 may be found which more closely approximate the D^d motif that might bind with higher affinity and stimulate more efficiently (5-7). 5 Also, C7 was not directly toxic to the cells in the absence of CTL.

Example 2: Identification Of Human Patients Exposed To HCV

Having identified an epitope for murine CTL, we 10 wanted to know whether it would be recognized by T cells from HCV seropositive patients as well. PBL from 8 HCV-seropositive patients, 2 individuals with chronic hepatitis B, and 2 healthy individuals were tested, with stimulation *in vitro*, for the lysis of autologous EBV-transformed cells or Con A blasts incubated with peptides at 10 μ M (Table 4). 15

Human CTL. We selected 8 individuals, patients from the Kagawa Medical School Medical Center (Kagawa, Japan), with HCV-specific serum antibodies detected by 20 anti-C100-3 (HCV Ab test, Ortho Diagnostic Systems) or second-generation enzyme immunoassay (EIA) tests (Abbott Laboratories, North Chicago, IL) specific for the putative core, NS3, and NS4 HCV proteins (C22, C33, and C100-3 antigens) and serum HCV RNA detected by the 25 double polymerase chain reaction method with two pairs of external and internal (nested) primers deduced from the 5'-non-coding region (49). Individuals coinfected with hepatotrophic viruses other than HCV detected by serological testing were excluded from the study. We 30 tested seven patients with chronic hepatitis C who had elevated serum levels of alanine aminotransferase (ALT) (80 to 450 IU/L for >1 year and one patient (#8) with acute hepatitis C who had recent onset of acute hepatitis with high serum level of ALT (1054 IU/L) and 35 was PCR-positive for HCV and seropositive by second generation EIA, but had no prior clinical history of hepatitis (Table 4). Two patients with chronic

hepatitis B (non C) detected by radioimmunoassay tests (positive for HBsAg and HBeAg; Abbott Laboratories, North Chicago, IL) and two healthy individuals seronegative for HCV and HBsAg were also tested.

TABLE 4. The response of PBL from HCV-seropositive individuals to C7

Patient no.	Age (yr)	Sex	ALT (IU/L)	anti-C100-3 (unit)	% specific lysis										
					C1	C2	C3	C4	C5	C6	C7	C8	C9	C10	C11
1	54	M	358	35.0								2			
2	49	M	119	16.0								-2			
3	44	M	132	18.0	2	2	2	2	2	2	0	3	4	3	3
4	66	M	80	12.0	5	2	2	1	1	2	3				
5	32	F	106	17.0	1	3	4	4	4	3	2	4	4	3	5
6	21	F	450	24.0	1	2	1	0	-1	1	0	1	2	1	0
7†	40	M	257	25.0	3	3	3	4	4	4	20	2	2	3	2
												#42			
8‡	58	F	1054	0.0*	4	4	4	4	5	4	25	4	4	4	4
9§	43	M	225									2			
10§	49	M	249									-2			
11†	28	F	17		0	-1	0	0	1	-2	2	1	1	1	0
12†	30	M	22									4			

PBL were stimulated *in vitro* with mitomycin C-treated PBL and each peptide 10 μ M, and tested against autologous target cells in the presence or absence of the corresponding peptide (10 μ M) at an E/T ratio of 100:1, as described in "Material and Methods". No toxicity of peptide against targets was observed. Two patients with chronic hepatitis B§ and two healthy individuals† did not show any response to C7 (<4%). ConA blast targets from PBL were used in patients No. 2, 5, and 8. Data are the means of triplicate samples with an SE of less than 5% and are representative of at least two independent experiments.

*HCV RNA+ and positive by second generation EIA, † PBL were stimulated twice *in vitro*, §HLA-A2.1 positive

In the human assays, lines derived from peripheral blood lymphocytes (PBL) of donors by Epstein-Barr virus (EBV) transformation (12) or Con A blast targets made from autologous PBL, as described previously (61), were 5 used as targets either in the presence of a peptide (10 μ M) or after infection with vHCV#4 (61). The PBL were separated on lymphocyte separating medium (LeucoPREP, Becton Dickinson, Mountain View, CA). The PBL (4x10⁶/ml in 24-well culture plates) were stimulated with 10 mitomycin C-treated PBL of the same donor (2x10⁶/ml in 24-well culture plates) in the presence of 10 μ M peptide at day 1 and 8, and 50 units/ml of human rIL2 (Cetus Corp., Emeryville, CA) added at day 2, 9, and 12 with fresh CTM. At day 8 or 15 of the culture, the 15 stimulated PBL were used as effectors and tested on targets of the EBV transformed lines or Con A blasts labeled overnight with 0.1 mCi of ⁵¹Cr. The 6-h ⁵¹Cr release assay was performed as described above.

The PBL from two patients (#7 and #8) were able to 20 specifically kill targets in the presence of C7 but not in the presence of other peptides or medium alone. None of the peptides tested was recognized by four other patients. Conversely, the PBL from four HCV-seronegative donors failed to kill the targets with the C7 peptide 25 (Table 4). The patients with acute and chronic hepatitis also showed cytotoxic activity against the targets infected with vHCV#4 and endogenously expressing HCV core protein.

For one of these two donors we were able to test 30 the phenotype of the effector cells. CTL activity from responder patient #7 with chronic hepatitis was blocked by anti-HLA class I (W6/32, IgG2a) but not by anti-HLA class II DR (L-243, IgG2a) (Fig.3). Thus, it is expected that these are conventional antigen-specific HLA class 35 I-restricted CD8⁺ CTLs. Patients #7 and #8 were HLA typed and found to express HLA-A1, A2, B51, Bw4, Bw6 and HLA-A2, B51, respectively. Moreover, we noted that the

C7 peptide sequence contained an HLA-A2-binding motif (22,34), with the sequence DLMGYIPLV. To ask whether the recognition of C7 by these patients' CTL was due to presentation of this nonamer sequence by HLA-A2, we 5 synthesized the corresponding nonamer peptide, designated C7A2, and tested recognition of both this and the full-length 16-mer, C7, by Patient #7 and #8 CTL on targets sharing or not sharing HLA-A2 (Fig. 4). The CTL killed autologous targets in the presence of C7 or the 10 nonamer C7A2, and also the HLA-A-and-B-negative cell line C1R transfected with HLA-A2, but not untransfected C1R or allogeneic targets lacking HLA-A2 (Fig. 4). Therefore, we conclude that the C7 peptide contains an 15 HLA-A2 motif-positive nonamer which is presented by HLA-A2 to human CTL of HCV-infected acute and chronic hepatitis patients.

These data showed that this peptide, recognized in the context of one murine MHC haplotype, can also be recognized in association with a human MHC molecule. 20 Recognition of the same 16-residue peptide by different T cells with both mouse and human class I MHC molecules could represent presentation of the same broadly recognized site by multiple class I molecules or could represent presentation of different partially overlapping positions of the peptide by different MHC molecules (20,25,55).

To distinguish these possibilities, we performed fine mapping of the murine C7 epitope using seven 25 overlapping decapeptides spanning the 16-residue peptide (see Fig. 2c). The only peptide that was as active or more active than the 16-mer was C7-A10. Indeed, this decapeptide appears to be the minimal peptide for the murine CTL, because the two nonapeptides contained within C7-A10 are also contained in one or the other of 30 the overlapping peptides C7-G10 and C7-P10M, which were much less active. (It is unlikely that these other decapeptides are inactive because of a failure in

processing, since the whole 16-mer is processed to an active form under the same conditions.) In comparison, in the case of the human response restricted by HLA-A2, we have identified at least one nonamer epitope as the 5 peptide DLMGYIPLV, which contains an HLA-A2-binding motif with anchor residues at positions 2 and 9 (22,34). This peptide constitutes the minimal human HLA-A2-restricted CTL epitope in this portion of the HCV core protein. However, because the H-2^d mice do not respond 10 to this nonamer peptide (Fig. 2c) and respond only weakly to the C7-G10 and C7-V10 peptides that contain this nonamer (Fig. 2c), the minimal epitopes recognized by mice and humans must not be identical, but closely overlapping. Indeed, all but one residue of the human 15 epitope are contained within the murine epitope. The similarity of core residues of C7 for recognition by mice and human is striking.

Recent reports of HCV sequence diversity allow comparison of several isolates ((11,29,42,48,70), 20 reviewed in (33)). The core protein is well conserved relative to the highly variable envelope glycoproteins E1 and E2. This hypervariability of the HCV envelope proteins suggests that these surface proteins may be under immunologic selective pressure for variation, as 25 has been suggested in the case of the HIV-1 envelope protein V3 loop, which is the principal neutralizing antibody domain as well as a determinant for CTL in both the human and the mouse (12,27,50,57,62). However, within the groups of HCV isolates (broadly subdivided by 30 comparison of all the reported HCV sequences) the core shows 95% to 100% sequence identity (33).

There are many lines of evidence that CTL can block outgrowth of virus (19,35,44,47,51,52,68,69). Because it is so well conserved, peptides from the HCV core protein, presented by class I MHC molecules to CD8⁺CD4⁻ 35 CTL of both mice and humans, are likely to be useful as a component of a broadly effective vaccine for HCV,

especially because HLA-A2 is the most prevalent human class I molecule, present in about 46% of the United States population. Also, in a small preliminary sampling of Japanese patients with hepatitis C in one of our 5 labs, 15 of 23 were HLA-A2⁺.

The prevalence of the HLA-A2 haplotype in human populations, together with the strong conservation of the C7 peptide among HCV isolates, indicates that the peptide C7 is useful as a diagnostic reagent in a large 10 proportion of the human population to detect exposure or infection with HCV of many strains.

It will be important to assess infected patients for a possible correlation between the clinical course 15 of hepatitis and the response to this peptide in HLA-A2-positive, HCV infected patients. Such analysis may reveal information of prognostic value. The presence of C7-specific CTL in a patient infected with HCV, might provide information as to whether the patient will clear the virus rapidly or go on to develop chronic liver 20 disease. This information could be useful in planning further treatment.

In our previous experience with HIV-1 proteins gp160 and reverse transcriptase, the epitopes seen by murine CTL were also seen by human CTL (12,30,62). 25 This is relevant in that this finding implies that the present method for identifying CTL epitopes in mice is generally useful for identification of peptides that are useful as vaccines and diagnostic reagents for human HCV retroviral infections.

30 Example 3: Additional Diagnostic Methods Using The Peptides Of The Present Invention

In addition to measurement of specific lysis of 35 target cells by CTL specific for the peptide reagent, other activities of CTL associated with antigen recognition can be assayed. For example, cytokines secreted in response to antigen activation of CTL can be assayed. A particularly preferred cytokine to be

measured is γ -interferon. Methods for measuring particular cytokines are well-known in the art. Two preferred formats are immunoassay of the cytokine and measurement of proliferation of a cytokine dependent 5 cell line.

Furthermore, the method described in Example 2 can be modified by elimination of the step of transforming the PBL from the patient with EBV. The viral transformation is done for laboratory purposes to 10 establish reproducible cell lines. For clinical assay purposes, the PBL can be cultured in the short term to sufficient numbers without transformation. Autologous concanavalin A-stimulated PBL blasts can be used as targets instead of EBV-transformed B-lymphoblastoid 15 cells. Also, targets are unnecessary in assays measuring γ -interferon secretion as the response of the antigen-specific CTL.

Example 4: Formulation Of Peptides As Pharmaceutical Compositions

20 The peptides of the present invention can be admixed with any pharmaceutically acceptable carrier, adjuvant or diluent. Preferably, pharmaceutical compositions of the present invention are prepared for intravenous, subcutaneous, intramuscular or intradermal 25 injection. In such formulations, the peptides are solubilized at such concentration as provides a dose ranging from 50 to 500 μ g. The solvent can be sterile saline or any other pharmaceutically acceptable solvent.

As to adjuvants, Incomplete Freund's Adjuvant (for 30 subcutaneous, intramuscular or intradermal injection) and QS21 can be used with both peptide and the whole protein. Alum can also be used as an adjuvant with the whole protein priming immunizations.

The peptides can be modified by coupling to a lipid 35 tail, as described by Deres, K. et al., *Nature* 342:561-564 (1989).

Furthermore, for intravenous injection, the

peptides might be modified to provide resistance to proteolytic degradation. A typical modification is to amidate the carboxyl terminus of the peptide. Methods for accomplishing these derivatizations of peptides are 5 well-known in the art.

Example 5: Administration Of Peptides As Vaccines For Prevention Of HCV Infection

10 The core protein and peptides, formulated as described in Example 3, can be administered as part of vaccination protocols typical in the art. Subjects are first primed by administration of HCV core protein, then boosted with administrations of the peptide. Whole

15 Whole protein administration is performed by injection, preferably intramuscularly or subcutaneously.

18 In addition to direct injection, peptides can also be administered by incubating the peptide with autologous PBMC for 2 hours, irradiating the incubated cells, and reinfusing intravenously, as described by Takehashi et al.. (74) and in co-pending application 20 08/031,494.

25 The HCV core protein can be provided by a recombinant vector expressing the entire protein. The recombinant vector is not particularly limited, but a preferred embodiment of the vector is one in which DNA encoding the HCV core protein is expressed from a vaccinia virus vector. The vHCV#4 vector, described in Example 1, is particularly preferred. The recombinant vector is administered by injection, either intravenously or intradermally. Alternatively, cells of 30 the patient can be transformed with the vector and the transformed cells can be infused into the patient or implanted under the skin.

35 Some time following priming, preferably one to two weeks later, the patient is then immunized with a peptide according to the present invention. The peptide is administered in a sufficient amount to elicit a CTL response to the immunizing peptide, as determined by any

known method for assaying such a CTL response. The method described in Example 2 is entirely suitable. Typically the peptide is administered in an amount of 50 to 500 μ g. Repeated boosting can be performed.

5 REFERENCES

The following articles of the scientific literature are cited in the present Specification. Each of these articles is hereby incorporated in its entirety by such reference.

- 10 1. Abastado, J. -P., C. Jaulin, M. -P. Schutze, P. Langlade-Demoyen, F. Plata, K. Ozato, and P. Kourilsky, *J. Exp. Med.* 166:327-340 (1987).
- 15 2. Alter, H. J., R. H. Purcell, J. W. Shih, J. C. Melpolder, M. Houghton, Q. -L. Choo, and G. Kuo., *N. Engl. J. Med.* 321:1494-1500 (1989).
3. Benacerraf, B., *J. Immunol.* 120:1809-1812 (1978).
4. Berzofsky, J. A., *J. Acq. Immune Defic. Syndromes* 4:451-459 (1991).
5. Berzofsky, J. A., *Annals N. Y. Acad. Sci.* 690:256-264 (1993).
- 20 6. Bodmer, H. C., R. M. Pemberton, J. B. Rothbard, and B. A. Askonas., *Cell* 52:253-258 (1988).
7. Boehncke, W. -H., T. Takeshita, C. D. Pendleton, S. Sadegh-Nasseri, L. Racioppi, R. A. Houghten, J. A. Berzofsky, and R. N. Germain., *J. Immunol.* 150:331-341 (1993).
- 25 8. Bradley, D. W., K. A. McCaustland, E. H. Cook, C. A. Schable, J. W. Ebert, and J. E. Maynard., *Gastroenterology* 88:773-779 (1985).
9. Chakrabarti, S., M. Robert-Guroff, F. Wong-Staal, R. C. Gallo, and B. Moss, *Nature* 320:535-537 (1986).
- 30 10. Choo, Q. -L., G. Kuo, A. J. Weiner, L. R. Overby, D. W. Bradley, and M. Houghton., *Science* 244:359-362 (1989).
- 35 11. Christiano, K., A. M. Di Bisceglie, J. H. Hoofnagle, and S. M. Feinstone., *Hepatology* 14:51-55 (1991).

12. Clerici, M., D. R. Lucey, R. A. Zajac, R. N. Boswell, H. M. Gebel, H. Takahashi, J. Berzofsky, and G. M. Shearer., *J. Immunol.* 146:2214-2219 (1991).
- 5 13. Cornette, J. L., H. Margalit, C. DeLisi, and J. A. Berzofsky., *Methods in Enzymol.* 178:611-634 (1989).
14. Cornette, J. L., H. Margalit, C. DeLisi, and J. A. Berzofsky., *The amphipathic Helix as a structural feature involved in T-cell recognition*, p. 333-346.
- 10 15. In R. M. Epend (ed.), *The Amphipathic Helix*. CRC Press, Boca Raton (1993).
16. Corr, M., L. F. Boyd, E. A. Padlan, and D. H. Margulies, *J. Exp. Med.* 178:1877-1892 (1993).
- 15 17. DeGroot, A. S., M. Clerici, A. Hosmalin, S. H. Hughes, D. Barnd, C. W. Hendrix, R. A. Houghten, G. M. Shearer, and J. A. Berzofsky., *J. Infect. Dis.* 164:1058-1065 (1991).
18. DeLisi, C. and J. A. Berzofsky, *Proc. Natl. Acad. Sci. U. S. A.* 82:7048-7052 (1985).
- 20 19. Di Bisceglie, A. M. and J. H. Hoofnagle., *Hepatology* 13:601-603 (1991).
21. Earl, P. L., B. Moss, R. P. Morrison, K. Wehrly, J. Nishio, and B. Chesebro., *Science* 234:728 (1986).
- 20 22. Elliott, T., V. Cerundolo, J. Elivn, and A. Townsend, *Nature* 351:402-406 (1991).
- 25 23. Evans, G. A., D. H. Margulies, B. Shykind, J. G. Seidman, and K. Ozato, *Nature* 300:755-757 (1982).
24. Falk, K., O. Rötzschke, S. Stevanovic, G. Jung, and H. -G. Rammensee, *Nature* 351:290-296 (1991).
- 30 25. Farci, P., H. J. Alter, S. Govindarajan, D. C. Wong, R. Engle, R. R. Lesniewski, I. K. Mushahwar, S. M. Desai, R. H. Miller, N. Ogata, and R. H. Purcell, *Science* 258:135-140 (1992).
26. Feinstone, S. M., H. J. Alter, H. P. Dienes, Y. Shimizu, H. Popper, D. Blackmore, D. Sly, W. T. London, and R. H. Purcell, *J. Infect. Dis.* 144:588-598 (1981).

25. Gammon, G., H. M. Geysen, R. J. Apple, E. Pickett, M. Palmer, A. Ametani, and E. E. Sercarz, *J. Exp. Med.* 173:609-617 (1991).
26. Germain, R. N. and D. H. Margulies, *Annu. Rev. Immunol.* 11:403-450 (1993).
- 5 27. Goudsmit, J., C. Debouck, R. H. Meloen, L. Smit, M. Bakker, D. M. Asher, A. V. Wolff, C. J. Gibbs, Jr., and D. C. Gajdusek, *Proc. Natl. Acad. Sci. U. S. A.* 85:4478-4482 (1988).
- 10 28. He, L. -F., D. Alling, T. Popkin, M. Shapiro, H. J. Alter, and R. H. Purcell, *J. Infect. Dis.* 156:636-640 (1987).
29. Hijikata, M., N. Kato, Y. Ootsuyama, M. Nakagawa, S. Ohkoshi, and K. Shimotohno, *Biochem. Biophys. Res. Commun.* 175:220-228 (1991).
- 15 30. Hosmalin, A., M. Clerici, R. Houghten, C. D. Pendleton, C. Flexner, D. R. Lucey, B. Moss, R. N. Germain, G. M. Shearer, and J. A. Berzofsky, *Proc. Natl. Acad. Sci. U. S. A.* 87:2344-2348 (1990).
- 20 31. Houghten, R. A., *Proc. Natl. Acad. Sci. USA.* 82:5131-5135 (1985).
32. Houghton, M., Q. -L. Choo, and G. Kuo, *European Patent Application 88310922.5:31-8216* (1988).
- 25 33. Houghton, M., A. Weiner, J. Han, G. Kuo, and Q. -L. Choo, *Hepatology* 14:381-388 (1991).
34. Hunt, D. F., R. A. Henderson, J. Shabanowitz, K. Sakaguchi, H. Michel, N. Sevilir, A. L. Cox, E. Appella, and V. H. Engelhard, *Science* 255:1261-1263 (1992).
- 30 35. Imawari, M., M. Nomura, T. Kaieda, T. Moriyama, K. Oshimi, I. Nakamura, T. Gunji, S. Ohnishi, T. Ishikawa, H. Nakagama, and F. Takaku, *Proc. Natl. Acad. Sci. USA* 86:2883-2887 (1989).
36. Kato, N., M. Hijikata, Y. Ootsuyama, M. Nakagawa, S. Ohkoshi, T. Sugimura, and K. Shimotohno, *Proc. Natl. Acad. Sci. USA* 87:9524-9528 (1990).
- 35 37. Kiyosawa, K., T. Sodeyama, E. Tanaka, Y. Gibo, K.

Yoshizawa, Y. Nakano, S. Furuta, Y. Akahane, K. Nishioka, R. H. Purcell, and H. J. Alter, *Hepatology* 12:671-675 (1990).

38. Koziel, M. J., D. Dudley, J. T. Wong, J. Dienstag, M. Houghton, R. Ralston, and B. D. Walker, *J. Immunol.* 149:3339-3344 (1992).

39. Le, A. -K. T., E. J. Bernhard, M. J. Holterman, S. Strub, P. Parham, E. Lacy, and V. H. Engelhard, *J. Immunol.* 142:1366-1371 (1989).

10 40. Margalit, H., J. L. Spouge, J. L. Cornette, K. Cease, C. DeLisi, and J. A. Berzofsky, *J. Immunol.* 138:2213-2229 (1987).

41. Margulies, D. H., G. A. Evans, K. Ozato, R. D. Camerini-Otero, K. Tanaka, E. Appella, and J. G. Seidman, *J. Immunol.* 130:463 (1983).

15 42. Maeno, M., K. Kaminaka, H. Sugimoto, M. Esumi, N. Hayashi, K. Komatsu, K. Abe, S. Sekiguchi, M. Yano, K. Mizuno, and T. Shikata, *Nucleic Acids Research* 18:2685-2689 (1990).

20 43. McCluskey, J., L. Boyd, M. Foo, J. Forman, D. H. Margulies, and J. A. Bluestone, *J. Immunol.* 137:3881-3890 (1986).

44. Mondelli, M., G. M. Vergani, A. Alberti, D. Vergani, B. Portmann, A. L. W. F. Eddleston, and R. Williams, *J. Immunol.* 129:2773-2778 (1982).

25 45. Murre, C., E. Choi, J. Weis, J. G. Seidman, K. Ozato, L. Liu, S. J. Burakoff, and C. S. Reiss, *J. Exp. Med.* 160:167-178 (1984).

46. Myers, G., S. F. Josephs, J. A. Berzofsky, A. B. Rabson, T. F. Smith, and F. Wong-Staal, *Human retroviruses and AIDS 1989*. Los Alamos National Laboratory, New Mexico (1989).

30 47. Naumov, N. V., M. Mondelli, G. J. M. Alexander, R. S. Tedder, A. L. W. F. Eddleston, and R. Williams, *Hepatology* 4:63-68 (1984).

35 48. Ogata, N., H. J. Alter, R. H. Miller, and R. H. Purcell, *Proc. Natl. Acad. Sci. USA* 88:3392-3396

(1991).

49. Okamoto, H., S. Okada, Y. Sugiyama, T. Tanaka, Y. Sugai, Y. Akahane, A. Machida, S. Mishiro, H. Yoshizawa, Y. Miyakawa, and M. Mayumi, Japanese J. Exp. Med. 60:215-222 (1990).

50. Parker, T. J., M. E. Clark, A. J. Langlois, T. J. Matthews, K. J. Weinhold, R. R. Randall, D. P. Bolognesi, and B. F. Haynes, Proc. Natl. Acad. Sci. U. S. A. 85:1932-1936 (1988).

10 51. Pasternack, M. S., Adv. Intern. Med. 33:17-44 (1988).

52. Plata, F., P. Langlade-Demoyen, J. P. Abastado, T. Berbar, and P. Kourilsky, Cell 48:231-240 (1987).

15 53. Prince, A. M., B. Brotman, T. Huima, D. Pascual, M. Jaffery, and G. Inchauspé, J. Infect. Dis. 165:438-443 (1992).

54. Realdi, G., A. Alberti, M. Rugge, A. M. Rigoli, F. Tremolada, L. Schivazzappa, and A. Ruol, Gut 23:270-275 (1982).

20 55. Reddehase, M. J., J. B. Rothbard, and U. H. Koszinowski, Nature 337:651-653 (1989).

56. Rosenthal, A. S., Immunol. Rev. 40:136-152 (1978).

25 57. Rusche, J. R., K. Javaherian, C. McDanal, J. Petro, D. L. Lynn, R. Grimalia, A. Langlois, R. C. Gallo, L. O. Arthur, P. J. Fischinger, D. P. Bolognesi, S. D. Putney, and T. J. Matthews, Proc. Natl. Acad. Sci. U. S. A. 85:3198-3202 (1988).

58. Sarmiento, M., A. L. Glasebrook, and F. W. Fitch, J. Immunol. 125:2665-2672 (1980).

30 59. Schwartz, R. H., Annu. Rev. Immunol. 3:237-261 (1985).

60. Shirai, M., T. Akatsuka, C. D. Pendleton, R. Houghten, C. Wychowski, K. Mihalik, S. Feinstone, and J. A. Berzofsky, J. Virol. 66:4098-4106 (1992).

35 61. Shirai, M., C. D. Pendleton, and J. A. Berzofsky, J. Immunol. 148:1657-1667 (1992).

62. Takahashi, H., J. Cohen, A. Hosmalin, K. B. Cease, R. Houghten, J. Cornette, C. DeLisi, B. Moss, R. N. Germain, and J. A. Berzofsky, Proc. Natl. Acad. Sci. USA 85:3105-3109 (1988).
- 5 63. Takahashi, H., R. Houghten, S. D. Putney, D. H. Margulies, B. Moss, R. N. Germain, and J. A. Berzofsky, J. Exp. Med. 170:2023-2035 (1989).
- 10 64. Takahashi, H., S. Merli, S. D. Putney, R. Houghten, B. Moss, R. N. Germain, and J. A. Berzofsky, Science 246:118-121 (1989).
65. Takamizawa, A., C. Mori, I. Fuke, S. Manabe, S. Murakami, J. Fujita, E. Onishi, T. Andoh, I. Yoshida, and H. Okayama, J. Virol. 65:1105-1113 (1991).
- 15 66. Townsend, A. and H. Bodmer, Annu. Rev. Immunol. 7:601-624 (1989).
67. Townsend, A. RM., J. Rothbard, F. M. Gotch, G. Bahadur, D. Wraith, and A. J. McMichael, Cell 44:959-968 (1986).
- 20 68. Tsubota, H., C. I. Lord, D. I. Watkins, C. Morimoto, and N. L. Letvin, J. Exp. Med. 169:1421-1434 (1989).
69. Walker, C. M., D. J. Moody, D. P. Stites, and J. A. Levy, Science 234:1563-1566 (1986).
- 25 70. Weiner, A. J., M. J. Brauer, J. Rosenblatt, K. H. Richman, J. Tung, K. Crawford, F. Bonino, G. Saracco, Q. -L. Choo, M. Houghton, and J. H. Han, Virology 180:842-848 (1991).
71. Weiner, A. J., H. M. Geysen, C. Christopherson, J. E. Hall, T. J. Mason, G. Saracco, F. Bonino, K. Crawford, C. D. Marion, K. A. Crawford, M. Brunetto, P. J. Barr, T. Miyamura, J. McHutchinson, and M. Houghton, Proc. Natl. Acad. Sci. U. S. A. 89:3468-3472 (1992).
- 30 72. Wilde, D. B., P. Marrack, J. Kappler, D. P. Dialynas, and F. W. Fitch, J. Immunol. 131:2178-2183 (1983).

73. Zinkernagel, R. M. and P. C. Doherty, *Adv. Immunol.* 27:51-177 (1979).
74. Takehashi, H. et al., *International Immunology*, 5:849-857 (1993).
- 5 75. Margalit, H. et al., *J. Immunol.* 138:2213-2229 (1987).

SEQUENCE LISTING

(1) GENERAL INFORMATION:

5 (i) APPLICANT:
(A) NAME: Gov't. of the United States as
represented by the Department
of Health and Human
Services/National Institutes
of Health

10 (B) STREET: Box OTT
(C) CITY: Bethesda
(D) STATE OR PROVINCE: Maryland
(E) COUNTRY: United States of America
(F) POSTAL CODE: 20892

15 (ii) TITLE OF INVENTION: Hepatitis C Virus Core Peptide For
Stimulation of Cytotoxic T Lymphocytes
and Diagnosis of HCV Exposure

20 (iii) NUMBER OF SEQUENCES: 10

25 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Birch, Stewart, Kolasch & Birch
(B) STREET: 8110 Gatehouse Road, Suite 500 East
(C) CITY: Falls Church
(D) STATE: Virginia
(E) COUNTRY: U.S.A.
(F) ZIP: 22042

30 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

35 (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: US 08/224,973
(B) FILING DATE: 08-APR-1994
(C) CLASSIFICATION:

40 (vii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Svensson, Leonard R.
(B) REGISTRATION NUMBER: 30,330
(C) REFERENCE/DOCKET NUMBER: 1173-456P

(viii) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (703) 205-8000
(B) TELEFAX: (703) 205-8050
(C) TELEX: 248345

(2) INFORMATION FOR SEQ ID NO:1:

45 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

50 (ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Hepatitis C Virus

(B) STRAIN: H Isolate

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu

1

5

10

15

(2) INFORMATION FOR SEQ ID NO:2:

10 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

20 (vi) ORIGINAL SOURCE:

(A) ORGANISM: Hepatitis C Virus
(B) STRAIN: H Isolate

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu
1 5 10

25 (2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

35 (vi) ORIGINAL SOURCE:

(A) ORGANISM: Hepatitis C Virus
(B) STRAIN: H Isolate

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Met Gly Tyr Ile Pro Leu Val Gly Ala Pro
40 1 5 10

(2) INFORMATION FOR SEQ ID NO:4:

5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

15 (v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Hepatitis C Virus
(B) STRAIN: H Isolate

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

15 Leu Met Gly Tyr Ile Pro Leu Val Gly Ala
1 5 10

(2) INFORMATION FOR SEQ ID NO:5:

20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

25 (iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Hepatitis C Virus
(B) STRAIN: H Isolate

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
Asp Leu Met Gly Tyr Ile Pro Leu Val Gly
1 5 10

(2) INFORMATION FOR SEQ ID NO:6:

35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

40 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Hepatitis C Virus
- (B) STRAIN: H Isolate

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Ala Asp Leu Met Gly Tyr Ile Pro Leu Val
1 5 10

(2) INFORMATION FOR SEQ ID NO:7:

10 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

15 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Hepatitis C Virus
- (B) STRAIN: H Isolate

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu
1 5 10

(2) INFORMATION FOR SEQ ID NO:8:

25 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

35 (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Hepatitis C Virus
- (B) STRAIN: H Isolate

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro
1 5 10

40 (2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

10 (vi) ORIGINAL SOURCE:
(A) ORGANISM: Mus musculus
(B) STRAIN: H-2d

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 4..5
(D) OTHER INFORMATION: /label= Descriptor
15 /note= "May be Lys, Arg, or His"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 8..9
(D) OTHER INFORMATION: /label= Descriptor
20 /note= "Optional amino acid"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 9..10
(D) OTHER INFORMATION: /label= Descriptor
25 /note= "May be Leu, Ile, or Phe"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
Xaa Gly Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10

30 (2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
35 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

40 (vi) ORIGINAL SOURCE:
(A) ORGANISM: Hepatitis C Virus
(B) STRAIN: H Isolate

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
Asp Leu Met Gly Tyr Ile Pro Leu Val
45 1 5

CLAIMS

What is claimed is:

1. A purified peptide having an amino acid sequence of a portion of the core protein of Hepatitis C Virus, said portion being less than the entire naturally existing core protein, which stimulates a cytotoxic T lymphocyte response in a mammal, and which includes an amino acid sequence corresponding to a binding motif of a human HLA molecule.
- 10 2. A purified peptide of claim 1 wherein said binding motif of a human HLA molecule is selected from one of the motifs of Table 1.
3. A purified peptide of claim 1 which is 8 to 16 amino acids in length.
- 15 4. A purified peptide of claim 1, that is derived from an amino acid sequence shown in Figure 5.
5. A purified peptide having the amino acid sequence GFADLMGYIPLVGAPL, SEQ ID NO:1.
- 20 6. A purified peptide having the amino acid sequence DLMGYIPLV, SEQ ID NO:10.
7. A purified peptide having the amino acid sequence LMGYIPLVGA, SEQ ID NO:4.
- 25 8. A pharmaceutical composition comprising a peptide according to claim 1 and a pharmaceutically acceptable carrier.
9. A pharmaceutical composition comprising a peptide according to claim 4 and a pharmaceutically acceptable carrier.

10. A pharmaceutical composition comprising a peptide according to claim 5 and a pharmaceutically acceptable carrier.

11. A pharmaceutical composition comprising a peptide according to claim 6 and a pharmaceutically acceptable carrier.

12. A method for immunization of a subject against Hepatitis C Virus which comprises administration of a pharmaceutical composition of claim 8 to said subject.

10 13. A method for immunization of a subject against Hepatitis C Virus which comprises:

15 1) administering an amount of a recombinant vaccinia virus expressing the Hepatitis C Virus core protein that is effective for priming said subject against Hepatitis C Virus antigens;

2) administering an amount of a pharmaceutical composition according to claim 8 that is effective for eliciting cytotoxic T lymphocytes specific for said peptide in said subject.

20 14. A method for immunization of a subject against Hepatitis C Virus which comprises administration of a pharmaceutical composition of claim 9 to said subject.

25 15. A method for immunization of a subject against Hepatitis C Virus which comprises:

2) administering an amount of a recombinant vaccinia virus expressing the Hepatitis C Virus core protein that is effective for priming said subject against Hepatitis C Virus antigens;

30 2) administering an amount of a pharmaceutical composition according to claim 9 that is effective for eliciting cytotoxic T lymphocytes specific for said peptide in said subject.

16. A method for immunization of a subject against Hepatitis C Virus which comprises administration of a pharmaceutical composition of claim 10 to said subject.

17. A method for immunization of a subject against Hepatitis C Virus which comprises:

- 5 1) administering an amount of a recombinant vaccinia virus expressing the Hepatitis C Virus core protein that is effective for priming said subject against Hepatitis C Virus antigens;
- 10 2) administering an amount of a pharmaceutical composition according to claim 10 that is effective for eliciting cytotoxic T lymphocytes specific for said peptide in said subject.

18. A method for diagnosing exposure of a patient to Hepatitis C Virus or for predicting a patient's clinical course following Hepatitis C Virus infection, which comprises:

- 15 i) obtaining a sample of peripheral blood mononuclear cells from said patient;
- 20 ii) culturing said peripheral blood mononuclear cells together with a peptide according to claim 1 under conditions which promote the proliferation of cytotoxic T lymphocytes; and
- 25 iii) assaying the peptide specific cytotoxic T lymphocyte activity in said culture.

19. The method according to claim 18, wherein said assay for peptide specific cytotoxic T lymphocyte activity is selected from the group consisting of assaying target cell lysis, assaying secretion of a cytokine, and assaying proliferation of cytotoxic T lymphocytes.

20. A method for diagnosing exposure of a patient to Hepatitis C Virus or for predicting a patient's clinical course following Hepatitis C Virus infection, which comprises:

- 5 i) obtaining a sample of peripheral blood mononuclear cells from said patient;
- ii) culturing said peripheral blood mononuclear cells together with a peptide according to claim 4 under conditions which promote the proliferation of cytotoxic T lymphocytes; and
- 10 iii) assaying the peptide specific cytotoxic T lymphocyte activity in said culture.

21. The method according to claim 20, wherein said assay for peptide specific cytotoxic T lymphocyte activity is selected from the group consisting of assaying target cell lysis, assaying secretion of a cytokine, and assaying proliferation of cytotoxic T lymphocytes.

22. A method for diagnosing exposure of a patient to Hepatitis C Virus or for predicting a patient's clinical course following Hepatitis C Virus infection, which comprises:

- 20 i) obtaining a sample of peripheral blood mononuclear cells from said patient;
- ii) culturing said peripheral blood mononuclear cells together with a peptide according to claim 5 under conditions which promote the proliferation of cytotoxic T lymphocytes; and
- 25 iii) assaying the peptide specific cytotoxic T lymphocyte activity in said culture.

23. The method according to claim 22, wherein said assay for peptide specific cytotoxic T lymphocyte activity is selected from the group consisting of assaying target cell lysis, assaying secretion of a cytokine, and assaying proliferation of cytotoxic T lymphocytes.

1/6

Fig. 1

Sequences of Hepatitis C Virus Core Peptides

Pep- tide	Residue Nos.	Sequence
C1	(9-24)	R K T K R N T T N R R P Q D V E F
C2	(45-60)	G V R A T R K T S E R S Q P R G
C3	(68-83)	A R R P E G R T W A Q P G Y P W
C4	(99-114)	S P R G S R P S W G P T D P R R
C5	(111-126)	D P R R R S R N L G K V I D T L
C6	(117-133)	R N L G K V I D T L T C G F A D L
C7	(129-144)	G F A D L M G Y I P L V G A P L
C8	(140-156)	V G A P L G G A A R A L A H G V R
C9	(153-168)	H G V R V L E D G V N Y A T G N
C10	(162-177)	V N Y A T G N L P G C S F S I F
C11	(172-188)	S F S I F L L A L L S C L T V P
C7A2	(132-140)	D L M G Y I P L V

2/2




FIG. 2B




FIG. 2A

3/6




FIG. 2C

4/6




FIG. 3

5/6





FIG. 4 SUBSTITUTE SHEET (RULE 26)

6/6

Fig. 5

FDA	MSTNPKPQRTKTKRNTNRRQDVEFP - GGGQTVGGYILLPRGPRLGVRATRTKSERSQPR	59
NYBC	MSTNPKPQRTKTKRNTNRRQDVEFP - GGGQTVGGYILLPRGPRLGVRATRTKSERSQPR	59
CHIRON	MSTLPKPQRTKTKRNTNRRQDVEFP - GGGQTVGGYILLPRGPRLGVRATRTKSERSQPR	59
OKAYAMA	MSTNPKPQRTKTKRNTNRRQDVEFP - GGGQTVGGYILLPRGPRLGVRATRTKSERSQPR	59
KATO	MSTNPKPQRTKTKRNTNRRQDVEFP - GGGQTVGGYILLPRGPRLGVRATRTKSERSQPR	60
FDA	GRRQIPKARRPGRTRWQPGYFWPLYEMVRAGGRGDSCLIPVAGZMGPTDPRVGRALWV	119
NYBC	GRRQIPKARRPGRTRWQPGYFWPLYEMVRAGGRGDSCLIPVAGZMGPTDPRVGRALWV	119
CHIRON	GRRQIPKARRPGRTRWQPGYFWPLYEMVRAGGRGDSCLIPVAGZMGPTDPRVGRALWV	119
OKAYAMA	GRRQIPKARRPGRTRWQPGYFWPLYEMVRAGGRGDSCLIPVAGZMGPTDPRVGRALWV	119
KATO	GRRQIPKARRPGRTRWQPGYFWPLYEMVRAGGRGDSCLIPVAGZMGPTDPRVGRALWV	119
FDA	RSSIPPLAVRVRPHGVHTARRPSWRDRALAHGVRLVEDGVNTATGNLPGCSFSIIFLAL	179
NYBC	GKVIDLTTCGFAIDLGYPLVGAFLGAARALAHGVRLVEDGVNTATGNLPGCSFSIIFL	179
CHIRON	GKVIDLTTCGFAIDLGYPLVGAFLGAARALAHGVRLVEDGVNTATGNLPGCSFSIIFL	179
OKAYAMA	GKVIDLTTCGFAIDLGYPLVGAFLGAARALAHGVRLVEDGVNTATGNLPGCSFSIIFL	179
KATO	GKVIDLTTCGFAIDLGYPLVGAFLGAARALAHGVRLVEDGVNTATGNLPGCSFSIIFL	179
FDA	LSCLITVPASAYQVYRNNSGlyh	200
NYBC	ALLSCLITVPASAYVYRNNSG1	200
CHIRON	ALLSCLITVPASAY-----	192
OKAYAMA	ALLSCLITVPASAYevhnvsg1	200
KATO	LALCLIVZPSQPLRcaqvr	200

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 95/03935

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C07K14/18 A61K39/29 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	JOURNAL OF VIROLOGY, vol. 68, no. 5, May 1994 pages 3334-3342, M. SHIRAI ET AL. 'An Epitope in Hepatitis C Virus Core Region Recognized by Cytotoxic T Cells in Mice and Humans' see the whole document ---	1-12, 14, 16
P, X	WO-A-94 20127 (CYTEL CORP) 15 September 1994 * table 26, page 26 * * appendix I: peptide 1.0816 on page 100; peptide 1.0930 on page 107; see claims; examples ---	1-12, 14, 16 -/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *'A' document defining the general state of the art which is not considered to be of particular relevance
- *'B' earlier document but published on or after the international filing date
- *'L' document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *'O' document referring to an oral disclosure, use, exhibition or other means
- *'P' document published prior to the international filing date but later than the priority date claimed

'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

'&' document member of the same patent family

Date of the actual completion of the international search

21 August 1995

Date of mailing of the international search report

28.08.95

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epnl
 Fax: (+31-70) 340-3016

Authorized officer

Fuhr, C

INTERNATIONAL SEARCH REPORT

Intern'l Application No
PCT/US 95/03935

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT*		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO-A-95 12677 (INNOGENETICS NV ; LEROUX ROELS GEERT (BE); DELEYS ROBERT (BE); MAER) 11 May 1995 * seq ID Nos. 10 and 11 in table 1 on page 51 * see claims ---	1,2,4,8, 9,12,14, 16
X	DE-A-42 09 215 (BOEHRINGER MANNHEIM GMBH) 7 January 1993 * Sequence ID No. 7 * see claims; examples ---	1-4, 8-12,14, 16
X	DATABASE WPI Section Ch, Week 9507 Derwent Publications Ltd., London, GB; Class B04, AN 95-047903 & JP-A-06 327 482 (IMMUNO JAPAN KK), 29 November 1994 see abstract ---	1,2,4
X	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 89, April 1992 WASHINGTON US, pages 3190-3194, W.-M. CHING ET AL. 'Interaction of immune sera with synthetic peptides corresponding to the structural protein region of hepatitis C virus' * peptides no. 129 and 133 * see page 3190, right column, paragraph 3; figures 1,2; tables 1,2 see page 3193, right column, paragraph 2 - page 3194, left column, paragraph 4 -----	1-12

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/03935

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 12-17 because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 12-17 are directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the compound/compostion.
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern'l Application No

PCT/US 95/03935

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9420127	15-09-94	AU-B-	6359494	26-09-94
WO-A-9512677	11-05-95	AU-B-	7993294	23-05-95
DE-A-4209215	07-01-93	AU-B-	652851	08-09-94
		AU-A-	2197392	11-02-93
		CA-A-	2089576	05-01-93
		WO-A-	9301210	21-01-93
		EP-A-	0551460	21-07-93